{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:43:43Z","timestamp":1786995823465,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.pmr.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T20:03:02Z","timestamp":1712433782000},"page":"619-636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuropharmacology in Traumatic Brain Injury"],"prefix":"10.1016","volume":"35","author":[{"given":"Gabriel","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merideth","family":"Byl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Giao","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessen C.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pmr.2024.02.001_bib1","series-title":"Report to congress on traumatic brain injury in the United States: epidemiology and rehabilitation","year":"2015"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib2","first-page":"56","article-title":"GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.pmr.2024.02.001_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00001199-199912000-00009","article-title":"Traumatic brain injury in the United States: A public health perspective","volume":"14","author":"Thurman","year":"1999","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"6","key":"10.1016\/j.pmr.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/01.HTR.0000341435.52004.ac","article-title":"Prevalence of long-term disability from traumatic brain injury in the civilian population of the United States, 2005","volume":"23","author":"Zaloshnja","year":"2008","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1155\/2006\/460592","article-title":"Pharmacotherapy of posttraumatic cognitive impairments","volume":"17","author":"Arciniegas","year":"2006","journal-title":"Behav Neurol"},{"issue":"10","key":"10.1016\/j.pmr.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1212\/WNL.0000000000005928","article-title":"Comprehensive systematic review update summary: Disorders of consciousness","volume":"91","author":"Giacino","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.pmr.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1102609","article-title":"Placebo-Controlled Trial of Amantadine for Severe Traumatic Brain Injury","volume":"366","author":"Giacino","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pmr.2024.02.001_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3109\/02699059409151025","article-title":"Clinical use of amantadine in brain injury rehabilitation","volume":"8","author":"Nickels","year":"1994","journal-title":"Brain Inj"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/apmr.2001.20831","article-title":"Positive outcomes in traumatic brain injury\u2013vegetative state: Patients treated with bromocriptine","volume":"82","author":"Passler","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"10.1016\/j.pmr.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/0269905031000070279","article-title":"The use of dopamine enhancing medications with children in low response states following brain injury","volume":"17","author":"Patrick","year":"2003","journal-title":"Brain Inj"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/17518429709060937","article-title":"The use of methylphenidate in paediatric traumatic brain injury","volume":"1","author":"Hornyak","year":"1997","journal-title":"Pediatr Rehabil"},{"issue":"11","key":"10.1016\/j.pmr.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/02699050050191931","article-title":"Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine","volume":"14","author":"Peggy","year":"2000","journal-title":"Brain Inj"},{"issue":"9","key":"10.1016\/j.pmr.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/02699050400025091","article-title":"Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery","volume":"19","author":"Rivera","year":"2005","journal-title":"Brain Inj"},{"issue":"5","key":"10.1016\/j.pmr.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PHM.0b013e3181a0e3a0","article-title":"Incidence of Clinically Significant Responses to Zolpidem Among Patients with Disorders of Consciousness","volume":"88","author":"Whyte","year":"2009","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.pmr.2024.02.001_bib15","unstructured":"Rani Lindberg M. TRIUMPH Traumatic Brain Injury Guidelines: Management of Post Traumatic Brain Injury (TBI) Agitation. 2020 Aug."},{"issue":"4562","key":"10.1016\/j.pmr.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.7100929","article-title":"Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury","volume":"217","author":"Feeney","year":"1982","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib17","first-page":"30","article-title":"Agitation in closed head injury: haloperidol effects on rehabilitation outcome","volume":"66","author":"Rao","year":"1985","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1186\/s13063-020-04553-2","article-title":"Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial","volume":"21","author":"Phyland","year":"2020","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/jnp.2006.18.4.547","article-title":"A\u00a0pilot study of quetiapine treatment of aggression due to traumatic brain injury","volume":"18","author":"Kim","year":"2006","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib20","first-page":"CD003299","article-title":"Pharmacological management for agitation and aggression in people with acquired brain injury","author":"Fleminger","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.pmr.2024.02.001_bib21","first-page":"917","article-title":"The treatment of agitation during initial hospitalization after traumatic brain injury","volume":"73","author":"Brooke","year":"1992","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0003-9993(97)90266-5","article-title":"The agitated brain injured patient. Part 2: Pathophysiology and treatment","volume":"78","author":"Mysiw","year":"1997","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/jnp.12.3.395","article-title":"Agitated symptom response to divalproex following acute brain injury","volume":"12","author":"Chatham Showalter","year":"2000","journal-title":"J\u00a0Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.rehab.2015.10.003","article-title":"Drugs for behavior disorders after traumatic brain injury: Systematic review and expert consensus leading to French recommendations for good practice","volume":"59","author":"Plantier","year":"2016","journal-title":"Ann Phys Rehabil Med [Internet"},{"key":"10.1016\/j.pmr.2024.02.001_bib25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3389\/fneur.2019.01169","article-title":"The Efficacy and Harms of Pharmacological Interventions for Aggression After Traumatic Brain Injury-Systematic Review","volume":"10","author":"Hicks","year":"2019","journal-title":"Front Neurol"},{"issue":"7","key":"10.1016\/j.pmr.2024.02.001_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070838","article-title":"Current and Potential Pharmacologic Therapies for Traumatic Brain Injury","volume":"15","author":"Tani","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.pmr.2024.02.001_bib27","series-title":"Brain injury medicine- principles and practice","first-page":"1126","article-title":"Neuropharmacology: a neurorehab perspective","author":"Ripley","year":"2022"},{"issue":"9","key":"10.1016\/j.pmr.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"e0273998","DOI":"10.1371\/journal.pone.0273998","article-title":"Overview of systematic reviews: Management of common Traumatic Brain Injury-related complications","volume":"17","author":"Vasudevan","year":"2022","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pmr.2024.02.001_bib29","first-page":"3105","article-title":"A\u00a0review of seizures and epilepsy following traumatic brain injury","volume":"267","author":"Fordington","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/ana.22066","article-title":"A\u00a0review of paroxysmal sympathetic hyperactivity after acquired brain injury","volume":"68","author":"Perkes","year":"2010","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/JNN.0000000000000207","article-title":"Pharmacologic Management of Paroxysmal Sympathetic Hyperactivity After Brain Injury","volume":"48","author":"Samuel","year":"2016","journal-title":"J\u00a0Neurosci Nurs"},{"key":"10.1016\/j.pmr.2024.02.001_bib32","series-title":"Rehabilitation after traumatic brain injury","first-page":"133","article-title":"Pharmacologic Management of the patient with traumatic brain injury","author":"Ripley","year":"2018"},{"issue":"Pt A","key":"10.1016\/j.pmr.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2016.01.021","article-title":"Pharmacotherapy in rehabilitation of post-acute traumatic brain injury","volume":"1640","author":"Bhatnagar","year":"2016","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.pmr.2024.02.001_bib34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/jnnp-2020-324353","article-title":"Psychotropic and pain medication use in individuals with traumatic brain injury-a Swedish total population cohort study of 240 000 persons","volume":"92","author":"Molero","year":"2021","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.pmr.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1089\/neu.2008.0849","article-title":"Does traumatic brain injury increase risk for substance abuse?","volume":"26","author":"Bjork","year":"2009","journal-title":"J\u00a0Neurotrauma"},{"key":"10.1016\/j.pmr.2024.02.001_bib36","series-title":"Brain injury medicine","year":"2021"},{"issue":"6","key":"10.1016\/j.pmr.2024.02.001_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.300.6.711","article-title":"Prevalence of chronic pain after traumatic brain injury: a systematic review","volume":"300","author":"Nampiaparampil","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib38","first-page":"444","article-title":"Acetaminophen, Aspirin, and Caffeine in Combination Versus Ibuprofen for Acute Migraine: Results From a Multicenter, Double-Blind, Randomized, Parallel-Group, Single-Dose, Placebo-Controlled Study. Headache: The Journal of Head and Face Pain","volume":"46","author":"Goldstein","year":"2006"},{"key":"10.1016\/j.pmr.2024.02.001_bib39","article-title":"Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine","volume":"55","author":"Ramadan","year":"2000","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.pmr.2024.02.001_bib40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0b013e3182535d0c","article-title":"Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]","volume":"78","author":"Holland","year":"2012","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pmr.2024.02.001_bib41","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","article-title":"Calcitonin Gene\u2013Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine","volume":"350","author":"Olesen","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.pmr.2024.02.001_bib42","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.4065\/80.9.1126","article-title":"Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Silberstein","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00001199-200403000-00003","article-title":"Orally Delivered Baclofen to Control Spastic Hypertonia in Acquired Brain Injury","volume":"19","author":"Meythaler","year":"2004","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"9","key":"10.1016\/j.pmr.2024.02.001_bib44","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/apmr.2001.25141","article-title":"Prospective assessment of tizanidine for spasticity due to acquired brain injury","volume":"82","author":"Meythaler","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"10.1016\/j.pmr.2024.02.001_bib45","first-page":"CD008929","article-title":"Interventions for managing skeletal muscle spasticity following traumatic brain injury","volume":"11","author":"Synnot","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neucie.2020.12.001","article-title":"Sleep disorders in traumatic brain injury","volume":"32","author":"Paredes","year":"2021","journal-title":"Neurocirugia (English Edition)"},{"issue":"20","key":"10.1016\/j.pmr.2024.02.001_bib47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1212\/WNL.0b013e3181fd62a2","article-title":"Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury","volume":"75","author":"Kaiser","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002060-199601000-00016","article-title":"Successful treatment of post-traumatic narcolepsy with methylphenidate: a case report","volume":"75","author":"Francisco","year":"1996","journal-title":"Am J Phys Med Rehabil"},{"issue":"12","key":"10.1016\/j.pmr.2024.02.001_bib49","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3109\/02699052.2013.823663","article-title":"Evaluating the impact of treatment for sleep\/wake disorders on recovery of cognition and communication in adults with chronic TBI","volume":"27","author":"Wiseman-Hakes","year":"2013","journal-title":"Brain Inj"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/02699050902748356","article-title":"Prevalence and structure of symptoms at 3\u00a0months after mild traumatic brain injury in a national cohort","volume":"23","author":"Lannsj\u00f6","year":"2009","journal-title":"Brain Inj"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/02699052.2019.1683898","article-title":"Follow-up after 5.5 years of treatment with methylphenidate for mental fatigue and cognitive function after a mild traumatic brain injury","volume":"34","author":"Johansson","year":"2020","journal-title":"Brain Inj"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib52","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0306-4522(00)00019-1","article-title":"Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events","volume":"96","author":"Horvitz","year":"2000","journal-title":"Neuroscience"},{"issue":"25","key":"10.1016\/j.pmr.2024.02.001_bib53","doi-asserted-by":"crossref","first-page":"e6960","DOI":"10.1097\/MD.0000000000006960","article-title":"Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/HTR.0b013e31821ebfb3","article-title":"Cholinergic dysfunction and cognitive impairment after traumatic brain injury. Part 2: evidence from basic and clinical investigations","volume":"26","author":"Arciniegas","year":"2011","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"7","key":"10.1016\/j.pmr.2024.02.001_bib55","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.apmr.2003.10.014","article-title":"Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury","volume":"85","author":"Zhang","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"issue":"7","key":"10.1016\/j.pmr.2024.02.001_bib56","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/02699059409151010","article-title":"Oral physostigmine and impaired memory in adults with brain injury","volume":"8","author":"Cardenas","year":"1994","journal-title":"Brain Inj"},{"issue":"8","key":"10.1016\/j.pmr.2024.02.001_bib57","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/026990598122223","article-title":"Treatment of aggression and irritability after head injury","volume":"12","author":"Kant","year":"1998","journal-title":"Brain Inj"},{"issue":"2","key":"10.1016\/j.pmr.2024.02.001_bib58","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00004714-199004000-00009","article-title":"The Incidence of Seizures during Tricyclic Antidepressant Drug Treatment in a Brain-Injured Population","volume":"10","author":"Wroblewski","year":"1990","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.pmr.2024.02.001_bib59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/B978-0-444-64012-3.00015-0","article-title":"Psychopharmacology of traumatic brain injury","author":"Polich","year":"2019","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.neulet.2008.10.076","article-title":"Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury","volume":"448","author":"Kline","year":"2008","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.pmr.2024.02.001_bib61","first-page":"954","article-title":"Neuroleptic Malignant Syndrome in Traumatic Brain Injury Patients Treated With Haloperidol","volume":"66","author":"Bellamy","year":"2009","journal-title":"J\u00a0Trauma Inj Infect Crit Care"},{"issue":"17","key":"10.1016\/j.pmr.2024.02.001_bib62","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1001\/archinte.161.17.2091","article-title":"Cognitive and Other Adverse Effects of Diphenhydramine Use in Hospitalized Older Patients","volume":"161","author":"Agostini","year":"2001","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/TA.0b013e3182aafd15","article-title":"More harm than good","volume":"76","author":"Bhullar","year":"2014","journal-title":"J\u00a0Trauma Acute Care Surg"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib64","doi-asserted-by":"crossref","DOI":"10.1006\/ebeh.2001.0235","article-title":"Cognitive and Behavioral Effects of Antiepileptic Drugs","volume":"2","author":"Meador","year":"2001","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.pmr.2024.02.001_bib65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJM199008233230801","article-title":"A\u00a0Randomized, Double-Blind Study of Phenytoin for the Prevention of Post-Traumatic Seizures","volume":"323","author":"Temkin","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.pmr.2024.02.001_bib66","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1089\/neu.2018.6162","article-title":"Diazepam Inhibits Post-Traumatic Neurogenesis and Blocks Aberrant Dendritic Development","volume":"36","author":"Villasana","year":"2019","journal-title":"J\u00a0Neurotrauma"},{"issue":"5","key":"10.1016\/j.pmr.2024.02.001_bib67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11920-003-0074-5","article-title":"The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury","volume":"5","author":"Arciniegas","year":"2003","journal-title":"Curr Psychiatr Rep"},{"issue":"12","key":"10.1016\/j.pmr.2024.02.001_bib68","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3109\/02699052.2015.1060358","article-title":"Does anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay?","volume":"29","author":"Sakel","year":"2015","journal-title":"Brain Inj"},{"issue":"1","key":"10.1016\/j.pmr.2024.02.001_bib69","first-page":"26","article-title":"Pharmacological interventions for traumatic brain injury","volume":"53","author":"Talsky","year":"2011","journal-title":"Br Columbia Med J"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib70","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1097\/HTR.0000000000000710","article-title":"Fatigue After Traumatic Brain Injury: A Systematic Review","volume":"37","author":"Ali","year":"2022","journal-title":"J\u00a0Head Trauma Rehabil"},{"issue":"4","key":"10.1016\/j.pmr.2024.02.001_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.5863\/1551-6776-20.4.335","article-title":"Morphine: An Effective Abortive Therapy for Pediatric Paroxysmal Sympathetic Hyperactivity After Hypoxic Brain Injury","volume":"20","author":"Raithel","year":"2015","journal-title":"J\u00a0Pediatr Pharmacol Therapeut"}],"container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965124000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965124000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T03:33:41Z","timestamp":1719632021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047965124000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1047965124000123"],"URL":"https:\/\/doi.org\/10.1016\/j.pmr.2024.02.001","relation":{},"ISSN":["1047-9651"],"issn-type":[{"value":"1047-9651","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropharmacology in Traumatic Brain Injury","name":"articletitle","label":"Article Title"},{"value":"Physical Medicine and Rehabilitation Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmr.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}